Given the pathway’s importance in cancer biology and potential as a therapeutic target, further research into PI3K/AKT/mTOR inhibitors is warranted to improve the outcomes of gynecological cancers [94,96]. This evidence concerns the gene PIK3CA and female reproductive organ cancer.